Company News

Clarity’s Executive Chairperson, Dr Alan Taylor, said, "We are very pleased to welcome Ali to the Board as an independent Non‑Executive Director."

Telix Pharmaceuticals has opened a major facility in North Melbourne that brings radiochemistry laboratories, clinical product manufacturing, patient dose administration and imaging together under one roof.

Sydney-based Viral Vector Manufacturing Facility and Melbourne-headquartered Mirugen have signed a non-exclusive Letter of Intent to evaluate and potentially develop the company's AAV-based gene therapy candidate targeting Retinitis Pigmentosa.

Algorae Pharmaceuticals has appointed Troy Valentine as a Non-Executive Director, a move the company says will materially deepen its board capability in capital markets, life sciences governance and international listed-company leadership. 

Starpharma has launched a fully underwritten renounceable entitlement offer to raise approximately $32 million, strengthening its balance sheet and providing a pro forma cash balance of $44.5 million.

AusBiotech has announced a new partnership designed to provide its members with discounted access to Oktopi’s AI-informed platform and to expand the services available through the organisation's Business Solutions Program.

Immutep has reported mature overall survival data from the investigator‑initiated INSIGHT‑003 trial that it says offer a hopeful signal for eftilagimod alfa, known as efti, in first-line non‑squamous non‑small cell lung cancer.

OncoSil Medical has completed three manufacturing validation cycles with partner Cyclotek, producing more than 50 validation doses of its OncoSil device and establishing a dedicated Australian manufacturing capability.

CLINUVEL has announced that Health Canada has granted a Notice of Compliance allowing SCENESSE to be marketed in the country for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria, a rare metabolic disorder that causes debilitating phototoxic reactions and burns after brief exposure to visible light.

Patrys has struck a binding agreement with Yale that transfers ownership of the deoxymab intellectual property to the university while securing Patrys a 50 per cent share of any future commercialisation revenue directly attributable to the deoxymab portfolio.

Proteomics International Laboratories has secured a United States patent for PromarkerEndo, its proprietary blood test for diagnosing endometriosis, a development the company describes as a major step toward global commercialisation.

Researchers at Monash University say they have found a gene in animal models that could help explain why some women experience early loss of fertility and premature menopause.